Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
miRisten in Relapsed/Refractory AML
NCT07025564Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of miristen in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoint: Incidence of adverse events. Started Oct 2025; status: recruiting.
02
Drugs
miristen
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07025564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025564.